NCT03765762View on ClinicalTrials.gov

A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 15, 2019

Primary Completion Date

December 17, 2019

Study Completion Date

December 17, 2019

Conditions
Severe Alzheimer Disease
Interventions
DRUG

GRF6019

GRF6019 for IV infusion

OTHER

Placebo

Placebo for IV infusion

Trial Locations (6)

32132

Riverside Clinical Research, Edgewater

85037

Cognitive Clinical Trials, Phoenix

85209

Cognitive Clinical Trials, Mesa

85297

Cognitive Clinical Trials, Gilbert

92103

Pacific Research Network, San Diego

08755

Bio Behavioral Health, Toms River

Sponsors

Lead Sponsor

Alkahest, Inc.
All Listed Sponsors
lead

Alkahest, Inc.

INDUSTRY